dexamethasone intravitreal implant
Diabetic macular edema
Allergan, an AbbVie Company
NOC Status at Filing:
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with DME who are pseudophakic and have had an inadequate response to prior anti-vascular endothelial growth factors (VEGF) therapy.
For the treatment of adult patients with diabetic macular edema (DME) who are pseudophakic.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.